Congressional researchers are again noting that the Food and Drug Administration (FDA) has missed a legal deadline to publish a list of known cannabinoids and guidance on hemp product containers as federal laws for the crop and its derivatives are set to change later this year in a way that stakeholders argue will upend the existing market.
The agency’s failure to follow through on what lawmakers directed will make it harder to comply with the law, hemp industry operatives say.
As part of appropriations legislation that President Donald Trump signed last year, many hemp products that were legalized during his first term in office under the 2018 Farm Bill will be prohibited once again starting in November.
The spending also measure included separate provisions directing FDA and other relevant agencies to study the cannabinoid marketplace and develop lists of cannabis components as well as issue guidance on hemp product containers for serving sizes.
Specifically, after the bill was signed, FDA was given 90 days to publish 1) a list of “all cannabinoids known to FDA to be capable of being naturally produced” by cannabis 2) a list of “all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in
Read full article on Marijuana Moment
